Biotech Values

[DewDiligence]

ONTY—To be fair, success at the final analysis is still possible. The main problem for longs—as noted in #msg-70815718—is that we now know the efficacy is not extraordinarily strong, and hence the commercial prospects for Stimuvax are considerably bleaker even if the drug ends up being approved.